Pfizer Achieves Double Firsts With AAHRPP Status For Phase I Trials In Singapore
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Pfizer became the first pharma company to be accredited by the U.S.-based Association for the Accreditation of Human Research Protection Programs for its Phase I Clinical Research Unit in Singapore
You may also be interested in...
Singapore, UK Award Infectious Disease Research Grants As Singapore Continues To Build Biomedical Research Base
SINGAPORE - Singapore and the United Kingdom have awarded SGD$4.5 million ($3.2 million) in grants covering six infectious disease research projects conducted jointly by Singapore and UK universities. The diseases include gastric flu, hepatitis B, dengue fever and tuberculosis
Singapore, UK Award Infectious Disease Research Grants As Singapore Continues To Build Biomedical Research Base
SINGAPORE - Singapore and the United Kingdom have awarded SGD$4.5 million ($3.2 million) in grants covering six infectious disease research projects conducted jointly by Singapore and UK universities. The diseases include gastric flu, hepatitis B, dengue fever and tuberculosis
Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says
SINGAPORE - Pfizer expects to see drugs discovered and developed in Asia brought into the clinic in about three years, Pfizer's Pharma Therapeutics R&D Head Martin Mackay told local reporters April 7 during a press conference at the company's Clinical Research Unit at Raffles Hospital in Singapore